The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The Long-HER study: Clinical and molecular analysis of advanced HER2+ breast cancer treated with trastuzumab and associated to long-term survival.
Enrique Espinosa
Honoraria - Roche
Angelo Gámez-Pozo
No relevant relationships to disclose
Ramon Maria Perez Carrion
No relevant relationships to disclose
Luis Manso
No relevant relationships to disclose
Carmen Crespo
No relevant relationships to disclose
Cesar Mendiola
No relevant relationships to disclose
Isabel Alvarez
No relevant relationships to disclose
Mireia Margeli
No relevant relationships to disclose
Juan L. Bayo
No relevant relationships to disclose
Xavier Gonzalez
No relevant relationships to disclose
Ana Santaballa
No relevant relationships to disclose
Eva Ciruelos
No relevant relationships to disclose
Miguel Angel Cabrera
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose
Gustavo Catalan
No relevant relationships to disclose
José Valero Álvarez Gallego
No relevant relationships to disclose
Jose Miramon
No relevant relationships to disclose
Rocio Lopez Vacas
No relevant relationships to disclose
Pilar Zamora
Honoraria - Roche
Research Funding - Roche